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ABSTRACT
Stable reconstitution of vascular endothelial beds upon transplantation of progenitor cells repre-
sents an important challenge due to the paucity and generally limited integration/expansion
potential of most identiﬁed vascular related cell subsets. We previously showed that mouse
fetal liver (FL) hemato/vascular cells from day 12 of gestation (E12), expressing the Stem Cell
Leukaemia (SCL) gene enhancer transgene (SCL-PLAP1 cells), had robust endothelial engraftment
potential when transferred to the blood stream of newborns or adult conditioned recipients,
compared to the scarce vascular contribution of adult bone marrow cells. However, the speciﬁc
SCL-PLAP1 hematopoietic or endothelial cell subset responsible for the long-term reconstituting
endothelial cell (LTR-EC) activity and its conﬁnement to FL developmental stages remained
unknown. Using a busulfan-treated newborn transplantation model, we show that LTR-EC activi-
ty is restricted to the SCL-PLAP1VE-cadherin1CD452 cell population, devoid of hematopoietic
reconstitution activity and largely composed by Lyve11 endothelial-committed cells. SCL-PLAP1
Ve-cadherin1CD452 cells contributed to the liver sinusoidal endothelium and also to the heart,
kidney and lung microvasculature. LTR-EC activity was detected at different stages of FL devel-
opment, yet marginal activity was identiﬁed in the adult liver, revealing unknown functional dif-
ferences between fetal and adult liver endothelial/endothelial progenitors. Importantly, the
observations that expanding donor-derived vascular grafts colocalize with proliferating
hepatocyte-like cells and participate in the systemic circulation, support their functional integra-
tion into young livers. These ﬁndings offer new insights into the engraftment, phonotypical, and
developmental characterization of a novel endothelial/endothelial progenitor cell subtype with
multiorgan LTR-EC activity, potentially instrumental for the treatment/genetic correction of vas-
cular diseases. STEM CELLS 2016; 00:000–000
SIGNIFICANCE STATEMENT
Using the newborn transplantation model, we have characterized in the mouse fetal liver a
unique SCL-PLAP1Ve-cad1CD452 population endowed with stable multiorgan endothelial
reconstitution potential and mostly composed by endothelial committed cells. Considering clini-
cal applications, transplantation of SCL-PLAP1Ve-cad1CD452 cells may provide a more robust
neonatal vascular engraftment than adult bone marrow-derived or adult liver-derived endothe-
lial/endothelial progenitor cell populations, constituting a novel and highly promising source of
cells to study vascular reconstitution and repair in neonatal preclinical models and also might
help guide the derivation of long term reconstituting vascular progenitors from pluripotent
stem cells.
INTRODUCTION
Transplantation of vascular progenitor cells
with potential to engraft and long-term con-
tribute to functional endothelial vascular beds
in multiple organs has been proposed as an
important strategy for genetic correction of
vascular diseases, inducing vascular regenera-
tion and as a tool for manipulation of vascular
mediated organ homeostasis and growth
[1–3]. Evidence from several animal injury
models demonstrated that infusion of primary
and in vitro expanded postnatal circulating and
bone marrow (BM)-derived cells, selected by
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the expression of different endothelial and hematopoietic pro-
genitor associated markers, including the Flk11, VE-cadherin1
Lin2 (VE-cad1Lin2), CD311, KIT1Sca1Lin2, KIT1CD341Lin2 or
CD1331CXCR41 cell populations in the mouse [4–9], promot-
ed postnatal physiological and pathological neovascularization
in different organs, including the liver [10–12], heart [13, 14],
and kidney [15–18]. This has led to clinical trials of circulat-
ing/BM cell subsets for therapy of certain human vascular dis-
orders [19]. Apparently, infused cells participated in the
recovery of injured vasculature through the production of
paracrine factors that promote endogenous endothelial cell
(EC) growth and/or by direct incorporation/differentiation into
organ endothelial tubular structures. While paracrine neo-
angiogenic effects seem to be a BM-derived cell-mediated
common mechanism involved in short term vascular injury
recovery [6, 20–22], the long term incorporation potential of
BM-derived cell populations into organ vascular endothelium
is considered highly variable, depending on the injured model,
targeted organ or speciﬁc characteristics of the donor cell
population [8, 23]. Therefore, the search for cell sources with
substantial vascular endothelial potential and functional organ
integration capacity upon transplantation remains an impor-
tant area of research to be explored.
Distinct subsets of postnatal primary microvascular ECs,
able to stably reconstitute organ vascular beds upon transfer
to injured tissue [24, 25] and in particular liver sinusoidal
endothelial cells (LSECs), have been described. LSECs trans-
ferred to adult animals can efﬁciently integrate into and
reconstitute the liver sinusoidal endothelium of acutely
injured or regenerating livers [26–28], modulate liver regener-
ation [27, 29], ﬁbrosis [30, 31], and alleviate coagulation
defects [32]. Despite the fact that transfer of LSECs constitute
one of the most promising cell-based strategies for restoration
of vascular damage and organ homeostasis [33, 34], they dis-
play reduced plasticity when compared to circulating/BM-
derived endothelial progenitor cells (EPCs) and long term sur-
vival of the LSEC-derived grafts is only observed in the liver
[26], a factor that potentially restraints their use in applica-
tions involving systemic vascular pathologies.
Using intravenous cell transfer into myelo-ablated new-
born-mice, we found that cells from the FL, a predominant
hematopoietic organ at this stage, had a much superior con-
tribution potential to the endothelium of different organs
than postnatal BM cells [35]. Newborns present an active
organ growth and neovascularization activity, thereby it was
proposed that this might facilitate the engraftment of trans-
ferred EC/EPCs in different locations [35, 36]. The FL multior-
gan EC engraftment potential is hence referred as long-term
reconstituting EC (LTR-EC) activity, involving cell homing/lodg-
ing, differentiation to organ-associated endothelial types and
long term stabilization of the donor-derived vascular beds. In
the current study, we determine the hematopoietic and endo-
thelial reconstitution potential of different E12 FL SCL-PLAP1
cell subsets, characterized by the activation of the hematopoi-
etic stem cell/endothelial SCL-30Enhancer, derived from the
stem cell leukaemia (SCL) gene, a key transcription factor for
the normal development of hematopoietic progenitors and
blood vessels [37–40]. We isolate and characterize a novel
progenitor population that is strongly committed to the endo-
thelial lineage, likely responsible for the LTR-EC activity at dif-
ferent stages of FL development but functionally absent in
the adult liver. Furthermore, productive integration of the
grafted vasculature is supported by its association to prolifer-
ating hepatocyte-like foci together with participation in the
general circulation. To our knowledge, the here described FL
cell population represents a so far not recognized largely com-
mitted EC/EPC cell subset endowed with long-term and multi-
organ vascular reconstituting potential.
MATERIALS AND METHODS
Mice
Animals were maintained in the CABD animal care facility and
procedures performed under the guidance of the European
Community Legislation with the approval of ethical committee
of CSIC and Universidad Pablo de Olavide. Transgenic lines for
transplantation assays include the SCL30Enh-hPLAP mice,
expressing the human placental alkaline phosphatase (PLAP)
reporter gene [35, 39], the SCL-30Enh-Lacz mice expressing
the b-galactosidase reporter gene [41] and the actin-DsRed
mice expressing the DsRed-MST reporter gene under the actin
regulatory elements (Jackson Laboratories, stock 005441) [42].
Cell Preparation
To obtain fetal tissues, timed breeding of heterozygous/homozy-
gous SCL-30Enh-PLAP transgenic mice was established. Fetuses
were obtained from day 10 (E10) to day 14 (E14) of gestation. Cell
preparation procedures from embryonic/fetal and adult hemato-
poietic tissues were previously published [35, 43], (Supporting
Information). A fragment of yolk sac (YS) was used for embryo typ-
ing by staining with the PLAP substrate, nitroblue tetrazolium
(NBT) (Roche, Mannheim, Germany, www.lifescience.roche.com)
as described [39]. LSEC enriched nonparenchymal cell (NPC) frac-
tion was obtained from adult mouse livers by a two-step collage-
nase perfusion technique and gradient percoll centrifugation as
described [26, 29] with modiﬁcations (Supporting Information).
Flow Cytometry Analysis and Cell Sorting
Cell suspensions were stained, analyzed and separated by
ﬂow cytometry as previously described [35] (Sup. Informa-
tion). A FACSAria ﬂow cytometer equipped with two lasers
and run with a FACSDiva software (BD Biosciences, www.
bdbiosciences.com/eu) was used.
Newborn Transplantation Assay and Chimerism
Analysis
Transplantation assays were performed transferring cells to the
facial vein of wild type busulfan treated newborn mice as
described in detail [35, 44, 45] (Supporting Information). Long-
term hematopoietic and vascular reconstitution analysis was per-
formed at 3-8 months post-transplant. Mice were anesthetized,
blood collected from the heart and perfused with 50 ml Tris-
buffered saline containing 0.001% heparin. Hematopoietic organs
were homogenized in phosphate buffered saline (PBS) supple-
mented with 5% of foetal calf serum (FCS) (PBS 5%FCS). The liver,
heart, kidney and lung were ﬁxed in zinc solution (BD-Pharmingen,
San Diego, CA, www.bdbioscience.com). For studies related to
immuno-histological detection of proliferative markers and DsRed
reporter gene, mice were perfused with PBS and the liver ﬁxed in
4% formaldehyde solutions (Merck KGaA, Germany). Perfusion
was not performed on <4–weeks–old mice and when livers were
weighed.
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Hematopoietic engraftment was assessed by PCR for PLAP
and LacZ reporter genes on genomic DNA from peripheral
blood and hematopoietic organs and by FACS for PLAP and
CD45 expression in peripheral blood [35]. Mice were consid-
ered reconstituted when circulating SCL-PLAP1 cells repre-
sented at least 1%. Levels of hematopoietic chimerism were
also determined by semi-quantitative PCR for PLAP and LacZ
on genomic DNA from hematopoietic organs as published [35,
43] (Supporting Information). In some experiments, the DsRed
marker was used for multilineage hematopoietic contribution.
Vascular engraftment was assessed by systematic histologi-
cal screening for SCL-PLAP1 donor-derived sinusoidal vascular-
like clusters (v.c.) on liver sections by NBT staining [35] (Suppor-
itng Information). For quantiﬁcation of vascular engraftment on
NBT stained liver sections we determined the frequency of mice
positive for v.c. and the relative tissue area containing v.c.,
denominated vascular cluster area (v.c.a.), using the Image Anal-
ySIS software program V3.1.110, as detailed in Supporting Infor-
mation Figure 1C and Supporting Information. Heart, kidney,
and lung sections from selected mice were also screened by
NBT staining and scored as indicated in Supporting Information
Table 1. Triple immunostaining for PLAP, CD45 and Isolectin B4
(IsoB4) or CD31 was performed to conﬁrm the endothelial
nature of the v.c. as described [17, 35]. Costaining for Ki67, P-
H3 and albumin was assessed on 4% formaldehyde ﬁxed liver
sections from some 3 weeks old mice. Detection of DsRed ﬂuo-
rescence and PLAP immunostaining was performed on cryosec-
tions. For expanded immune-histological reagents, antibodies,
and methods refer to Supporting Information.
OP9 Endothelial Cord/Colony Forming Assay
OP9 stromal cell line, expressing GFP, was provided by J.C.
Zu~niga-Pﬂucker [46]. Cells were cocultured in 96-well plates
containing subconﬂuent OP9 cells in MEMa containing 10%
FCS, 1% P/S, 5x1025M 2b2mercaptoethanol (Sigma-Aldrich,
Steinheim, Germany, www.sigmaaldrich.com) and 50 ng/ml
VEGF (Cell Signaling Technology, www.cellsignal.com) [47, 48].
After 4 days, cells from duplicated wells were ﬁxed in Metha-
nol/DMSO 5% and stained for CD31 as described with modiﬁ-
cations [47] (Supporting Information). Sequential images
covering the area of each well were generated and single
CD311 cords and colonies counted. Images were obtained
with a Leica DMIRB inverted microscope including a Leica
DFC350FX digital camera (www.leica-microsystems.com).
Hematopoietic CFU-C Assay
Clonogenic Colony Forming Unit in Culture (CFU-C) for ery-
throid/myeloid progenitor assay was performed as described
[40]. In brief, FL sorted cells were transferred to 1.5 ml of
cytokine-supplemented methylcellulose medium (M3434,
StemCell Technologies, www.stemcell.com) and plated in
duplicates in 6-well plates. Hematopoietic colonies were
scored after 7 days under a Leica MZ7.5 stereoscope including
a Nikon DS5 digital camera and DSL1 control unit (http://
www.nikon.es/es_ES/).
B Lymphoid Culture Assay
OP9 B lymphoid differentiation/expansion assay was performed
as described [49, 50] with slight modiﬁcations. FL sorted cells
were cultured for 14 days on conﬂuent OP9 layers in 24-well
plates in supplemented MEMa containing IL-7 (50 U/ml) and
Flt3 ligand (10 ng/ml) (PetroTech, Rocky Hill, NJ, www.pepro-
tech.com). Cells were re-fed every 4 days and replated once
onto a new well with OP9 cells. Cells were analyzed by ﬂow
cytometry gating out 7AAD1 dead cells and GFP1 OP9 cells.
BrdU Treatment, Immuno-Detection and
Quantification
Mice received intraperitoneal (i.p.) injections of 5-Bromo-2-
DeoxyUridine (BrdU) (Sigma-Aldrich, Stenheim, Germany, www.
sigmaaldrich.com) (80 mg/kg body weight in 0.9% NaCl solution)
4 hours before analysis as described [51]. Vibratome thick liver
sections were immunostained for detection of BrdU, PLAP and
nuclei as described [51] (Supporting Information). Z-stack images
were taken with a Leica SP5 confocal MP-AOBS microscope (60-
80 optical slices of 0.5 lm depth). The number of total nuclei
and outline of tissue area per image was determined using the
Imaris software (Version 7.6.3).
Statistical Analysis
Student’s t test was used to compare mean6 SD from two
groups with parametric distribution. Comparison for donor-
derived vascular cluster area (v.c.a.) at different times post-
transplantation was evaluated using a nonparametric U-Mann–
Whitney test. Statistical signiﬁcance was deﬁned as p< .05.
Excel 14.3.4 and IBM-PSS Statistics 19 software were used.
RESULTS
Multiorgan Long Term Reconstituting Endothelial Cell
Activity is Identified in the SCL-PLAP1VE-cad1CD452
Cell Subset from E12 FL
FL cells expressing high levels of the SCL-30Enh-PLAP reporter
transgene (SCL-PLAP1 cells) presented long-term hematopoi-
etic and endothelial reconstitution activity upon transplanta-
tion [35, 39]. To determine whether long-term endothelial
reconstitution (LTR-EC) activity was associated to a speciﬁc
SCL-PLAP1 cell subset, cells were FACS sorted, i.v. trans-
planted to busulfan conditioned newborn recipient mice and
hematopoietic and endothelial contribution analyzed at >3
months. SCL-PLAP1 FL cells were fractionated based on the
surface expression of the EC receptor VE-cadherin (VE-cad),
expressed in the embryonic hemangioblasts [52], postnatal
subsets of EPCs [5] and hematopoietic stem and progenitor
cells (HSPCs) [47, 53, 54] and the pan-leukocyte marker CD45,
(Fig. 1A). Long-term engraftment analysis showed that most
animals transplanted with FL SCL-PLAP1VE-cad1 or SCL-
PLAP1VE-cad2 cells presented donor-derived hematopoietic
chimerism in peripheral blood as determined by FACS detec-
tion of the donor marker PLAP and in hematopoietic organs
by PCR-PLAP signal on genomic DNA, (Table 1, Supporting
Information Fig. 1A-C), consistent with previous reports [47].
However, while SCL-PLAP1VE-cad1 cells contributed to NBT-
positive liver sinusoidal endothelial vascular-like clusters (v.c.)
and to some endothelial-like cells in large vessels (Table 1,
Supporting Information Fig. 1D), only few nonendothelial-like
SCL-PLAP1VE-cad2 derived cells were observed in liver sec-
tions. Donor-derived ECs identity was then conﬁrmed by the
expression of the EC marker IsoB4 and the absence of the
hematopoietic marker CD45 [35, 55] (Supporting Information
Fig. 1E). FL SCL-PLAP1 cells subdivision based on expression
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of CD45 (Fig. 1A), showed that donor-derived sinusoidal v.c.
were only observed in animals transferred with SCL-
PLAP1CD452 cells and no contribution to liver ECs was
detected in SCL-PLAP1CD451 hematopoietic chimeras (Table
1). Further transfer of FL SCL-PLAP1VE-cad1CD452 and SCL-
PLAP1VE-cad1CD451 cells (Fig. 1A), revealed that donor-
Figure 1.
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derived liver sinusoidal v.c. and ECs within large vessels were
limited to mice transferred with the SCL-PLAP1VE-cad1CD452
population while hematopoietic reconstitution activity was
present in SCL-PLAP1VE-cad1CD451 cells (Table 1, Fig. 1B-E).
Of note, although FL SCL-PLAP1VE-cad1CD452 cells did not
present hematopoietic reconstitution potential (Fig. 1B-D),
sporadic donor-derived CD451 hematopoietic cells were
detected within the v.c. (Fig. 1E). Overall, endothelial contri-
bution analysis in the liver indicated that LTR-EC activity was
restricted to FL SCL-PLAP1VE-cad1CD452 cells.
Considering the reported endothelial-like phenotype of
the VE-cad1CD451 embryonic population endowed with HSPC
activity [47, 53], we looked in detail for donor-derived ECs in
SCL-PLAP1VE-cad1CD451 chimeras. Z-stack high resolution
confocal microscopy images from 20 individual SCL-PLAP1VE-
cad1CD451-derived PLAP1 cells, placed within the intima lay-
er in large vessels, showed that only 7 cells located in an
endothelial position facing the lumen and having a SCL-
PLAP1CD451IsoB1 hematopoietic/endothelial mix phenotype.
All other cells were peri-endothelial SCL-PLAP1CD451IsoB2
hematopoietic cells (Fig. 1F, Supporting Information Table 2).
Similar to long-term transplanted primary leukemia cells that
incorporated into the liver vascular endothelium as CD451
endothelial-like cells [56], this result suggested that rare
hematopoietic committed cells were able to preserve hemato-
poietic features upon endothelial integration. Nevertheless,
we cannot exclude the possibility that FL SCL-PLAP1VE-
cad1CD451 cells may contribute to CD452 ECs in other mod-
els of acute vascular damage, including retinal ischemia or
aggressive lung tumor models, as shown for transplanted
adult BM-derived HSCs/progeny or myeloid progenitors [7, 8].
We next analyzed the long-term endothelial contribution
in hearts and kidneys from selected chimeric mice, (Support-
ing Information Table 1). Endothelial vascular clusters in the
heart were only observed in mice transferred with SCL-
PLAP1VE-cad1 (2 out of 6 mice presenting liver sinusoidal
v.c.) (Supporting Information Fig. 1E) and SCL-PLAP1VE-
cad1CD452 cells (3 out of 9 analyzed mice, 2 of them pre-
senting liver sinusoidal v.c.), (Fig. 2). Detection of donor cells
in the kidneys was highly variable in mice presenting hemato-
poietic chimerism (SCL-PLAP1VE-cad1, SCL-PLAP1VE-cad2,
SCL-PLAP1CD451 and SCL-PLAP1VE-cad1CD451 chimeras), with
consistent detection of scattered and/or large clusters of donor-
derived SCL-PLAP1CD451 hematopoietic cells and total absence
of endothelial contribution (Supporting Information Figs. 1E, 2).
Donor-derived kidney ECs were only detected in SCL-
PLAP1CD452 (in 2 out of 3 mice presenting liver sinusoidal v.c.)
(Supporting Information Fig. 2) and SCL-PLAP1VE-cad1CD452
chimeras (in 3 out of 9 recipient mice) (Fig. 2). Importantly, we
also found an entire donor-derived nephron vascular network,
indicating that SCL-PLAP1VE-cad1CD452 cells were capable of
generating highly specialized ECs (Fig. 2). Furthermore, trans-
planted SCL-PLAP1VE-cad1CD452 cells also formed vascular
clusters in the lungs from all thee liver chimeras (Fig. 2). Over-
all, our results directly demonstrate that FL SCL-PLAP1VE-
cad1CD452 cells have multiorgan LTR-EC potential.
Most E12 FL SCL-PLAP1VE-cad1CD452 Cells are
Lyve11 Endothelial Cells
To further analyze the endothelial/hematopoietic lineage com-
mitment of the SCL-PLAP1VE-cad1CD452 population, limiting
dilution cultures assays for endothelial and hematopoietic pro-
genitor cells were performed. Endothelial potential was assessed
by the OP9/VEGF endothelial cord/colony formation assay, used
to test EC differentiation/growth activity from embryonic/fetal
cell subsets [47, 48]. SCL-PLAP1VE-cad1CD452 cells generated
CD31-positive ECs cords/colonies (806 12 colonies per 500
cells) whereas EC activity was almost absent from other SCL-
PLAP1 populations (Fig. 3A, 3B). Also, SCL-PLAP1VE-cad1CD452
cells were largely devoid of clonogenic myeloid/erythroid pro-
genitor CFU-C activity (Fig. 3C), supporting their commitment to
the endothelial lineage observed in vivo.
Next, we performed a phenotypic characterization and
determined the expression of endothelial and hematopoietic
markers. As the vast majority of VE-cad1 cells were included
within the SCL-PLAP1 population (Fig. 1A), the phenotype of
the VE-cad1 subsets was considered as a bona ﬁde represen-
tation of the SCL-PLAP1VE-cad1 phenotype. FACS analysis
revealed that most VE-cad1CD452 cells (876 5%) expressed
Lyve1, a marker for FL sinusoidal endothelium [57, 58], also
present in a minor fraction of VE-cad1CD451 cells potential-
ly representing pro-angiogenic myeloid cells [59] (Fig. 3D).
The presence of other pan-endothelial related markers
Figure 1. Long-term reconstituting endothelial cell activity is identiﬁed in the SCL-PLAP1VE-cad1CD452 cell subset from E12 FL. Cell
suspension was prepared from E12 FL SCL-30Enh-PLAP transgenics. (A): FACS proﬁles showing representative sorting windows according
to the expression of SCL-30Enh-PLAP (P1) transgene and VE-cad (V1), SCL-PLAP and CD45 (C1) and SCL-PLAP, VE-cad and CD45. Quad-
rants are set according to values obtained from unstained and single stained controls (left plots on P/V and P/C staining) on viable cells
(116 5% 7AAD1 dead cells). Percentage 6SD of cells in each quadrant and SCL-PLAPbright1 gated cells are indicated (n5 13). (B): Repre-
sentative FACS plots showing percentage6 SD of SCL-PLAP1CD451 hematopoietic cells in peripheral blood from SCL-30Enh-PLAP trans-
genics (n5 7) and transplanted mice with P1V1C- (n5 9) and P1V1C1 cells (n5 7). Results from three independent transplantation
experiments. (C): Semiquantitative PCR on genomic DNA from hematopoietic organs from representative P1V1C1 and P1V1C2 trans-
planted mice showing the levels of the donor markers PLAP and LacZ transgenes (from cotransplanted BM-LacZ cells). Numbers in PCR
gel images indicate the percentage of donor-marker contribution calculated by comparison with the control signal curve using Myo
gene as normalization control. (D): Percentage of donor cell chimerism in different hematopoietic organs (P1V1C2 chimeras, n5 4 from
two independent transplantation experiments; P1V1C1 chimeras, n5 6 from three independent transplantation experiments). (BM,
bone marrow; Thy, thymus; Sp, spleen; LN, lymph nodes; Bl, blood). (E): Representative liver sections from an SCL-30Enh-PLAP transgenic
mouse and a P1V1C2 chimera stained with nitroblue tetrazolium (NBT) (left images) and with antibodies for detection of PLAP, blood
cells (CD45), endothelial cells (IsoB4) and nuclei (DAPI). P1V1C2 cell contributed to sinusoidal vascular clusters containing SCL-
PLAP1CD452IsoB41 endothelial (arrows) and sporadic SCL-PLAP1CD451 blood cells (asterisks) (top images) and to the endothelium of
large vessels (lower images). (F): Liver sections from wild type and a P1V1C1 chimera showing PLAP1 donor cells mostly in perivascular
locations (top images). Z-stack images and orthogonal projections showing SCL-PLAP1CD451IsoB42 cells (asterisk) located behind the
IsoB41 endothelium (blue) and an SCL-PLAP1CD451IsoB41 cell (arrow) within the endothelium (Z-stacks from six optical images
acquired at 2 lm intervals). Scale bars NBT images 100 lm. Scale bars immunoﬂuorescence images 25 lm. Abbreviations: FSC, Forward
Side Scatter; PLAP, placental alkaline phosphatase reporter gene; SCL, stem cell leukaemia gene.
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(CD31, Tie2, Flk1, and CD34) and the absence of the hema-
topoietic receptor Mac-1, further reinforced the endothelial
nature of SCL-PLAP1VE-cad1CD452 cells (Fig. 3D). Very few
KIT1 cells (56 2%) were found within the VE-cad1CD452
population (Fig. 3D), a marker associated with embryonic VE-
cad1 hemogenic endothelium [49] and early HSPCs [50, 60,
Table 1. Hematopoietic and liver vascular engraftment potential of E12 FL SCL-PLAP1 cell populations
Donor cells
Hematopoietic chimerism Vascular chimerism
Population Cell n 3 104 (ee)
n PLAP1/
Total micea
% PLAP1
(Range values)b
n PLAP1/
Total micec (%)
PLAP1 v.c.a. (31023 cm2)
(Range values)
VE-cad1 1-3 8/12 7.76 4.4 6/8 0.426 0.44
(3-8) (1.4-14) (75) (0.004-1.05)
VE-cad- 5-15 7/8 9.86 8 0/7 0
(2-8) (1-22) (0)
CD451 2-8 19/27 7.66 4.5 0/19 0
(3-5) (1.7-15) (0)
CD45- 2-5 0/17 0 3/13 0.156 0.05
(3) (23) (0.09-0.19)
VE-cad1CD451 1-2 9/14 13.86 3.8 0/9 0
(4-6) (8-19) (0)
VE-cad1CD45- 1-2 0/9 0 3/9 106 14
(3-6) (33) (0.18-4.7-27)
Mice were i.v. transferred with the indicated number of FL sorted SCL-PLAP1 populations plus 1 x 106 BM-LacZ1 cells and analysed at 3-
8 months post-transplant for hematopoietic and vascular engraftment. SCL-PLAP1 hematopoietic chimerism was determined in peripheral blood
leukocytes by PCR-PLAP and ﬂow cytometry.
aOnly mice presenting PLAP and/or LacZ PCR signal in circulation are included in the study. The number of PLAP1 chimeras related to the total
analysed mice is indicated.
bMean values for the % of SCL-PLAP1CD451 leukocytes in the host circulation assessed by ﬂow cytometry. All hematopoietic chimeras were
positive for PCR-PLAP signal in hematopoietic organs. Signiﬁcant increment on long-term circulating donor-derived cells were obtained from
SCL-PLAP1VE-cad1CD451 chimeras compared to SCL-PLAP1VE-cad1 and SCL-PLAP1CD451 chimeras (p< ,05, Student’s t test), potentially
reﬂecting an enrichment on HSCs. Vascular chimerism was determined by histological NBT detection of SCL-PLAP1 donor-derived cells forming
vascular-like clusters (v.c.) on liver sections (Supporting Information Fig. 1D) and animals scored as positive when at least one v.c. was observed.
cThe number and percentage of animals presenting SCL-PLAP1 v.c. in liver sections from the total number of SCL-PLAP1 hematopoietic chimeras
is shown, except for mice transplanted with SCL-PLAP1CD45- and SCL-PLAP1VE-cad1CD45- cells that did not present FL derived hematopoietic
engraftment in circulation, (see Supporting Information Table 1 for individual values). The mean values of tissue area containing SCL-PLAP1 v.c.
referred to the total tissue area analysed are indicated for each group, (PLAP1 v.c.a.). The mean6 SD and range values obtained from vascular
chimeras from each group are shown (see Supporting Information Table 1 for individual values). Data was obtained from 3 to 6 independent
transplantation experiments for each population.
Abbreviations: ee, embryo equivalent; PLAP, placental alkaline phosphatase reporter gene.
Figure 2. SCL-PLAP1VE-cad1CD452 cells present long-term reconstitution endothelial cell activity in different organs. SCL-PLAP1VE-
cad1CD452 chimeras were analyzed for endothelial engraftment in different organs. (A): NBT staining on tissue sections obtained from
indicated organs from a SCL-3’Enh-PLAP transgenic mouse and from a representative SCL-PLAP1VE-cad1CD452 chimera. (B): Images
from stained sections with antibodies anti-PLAP, anti-CD45, and IsoB4/anti-CD31 and DAPI (nuclei). Most donor-derived cells are
PLAP1CD45-IsoB41/CD311 endothelial cells (arrows). Sporadic SCL-PLAP1CD451 hematopoietic cells are also detected (asterisk). Mice
analyzed, n5 9. Heart and kidney endothelial contribution was observed in 4 and 3 mice, respectively; lung endothelial contribution
was observed in 3 mice. Scale bars 25 lm. Abbreviation: PLAP, placental alkaline phosphatase reporter gene.
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61]. Indeed, cultured VE-cad1CD452KIT1 cells showed some
CD191 B cells activity (Supporting Information Fig. 3).
Together, in vitro differentiation and phenotypic analysis
indicated that the SCL-PLAP1VE-cad1CD452 population is
mostly composed by endothelial committed Lyve11 cells and
unveiled its limited hematopoietic potential.
Figure 3. E12 FL SCL-PLAP1VE-cad1CD452 population is largely composed by endothelial lineage committed Lyve11 cells. (A): FL cell
fractions were separated by FACS according to the indicated representative sorting windows and in vitro endothelial and hematopoietic
potential determined. (B): Endothelial assays. Sorted cells were cultured on OP9 feeder cells for 4 days, stained with anti-CD31 antibody
and the number of CD311 EC cord/colonies enumerated. Representative images from wells plated with 500 P1V1C- cells and 2,000
P1V1C1 cells are shown. The mean colony number 6SD per well plated with the indicated cell type and number is shown. EC activity
was largely restricted to P1V1C2 cells, a mean value of 80 CD311 EC cords/colonies were produced by 500 P1V1C- cells and extensive
EC network by 2,000 cells (not shown). The number of scored wells was as follows: P1V1C2, n5 9; P1V1C1, n5 4; P1V-C2, n5 5;
P1V2C1, n5 5. Data collected from at least 2 independent experiments. (C): CFU-C myeloid/erythroid colony assays. Representative
images from wells plated with 104 P1V1C- and 103 P1V1C1 cells cultured for 7 days. P1V1C2 cells did not present clonogenic CFU-C
hematopoietic progenitor potential. The mean colony number 6SD per well is shown. The number of scored wells was as follows:
P1V1C2, n5 6; P1V1C1, n5 6; P1V-C2, n5 6; P1V-C1, n5 4. Data collected from three independent cell culture experiments. (D):
Flow cytometry analysis of viable FL populations subdivided according to the expression of VE-cad (V) and CD45 (C). VE-cad1 cells repre-
sent a subpopulation of SCL-PLAP1 cells, (see Figure 1A). Representative histograms including unstained control (gray line) and speciﬁc
antibody staining (black) are presented. Higher levels of endothelial markers (Lyve1, CD31, Tie2, Flk1, CD34), lack of expression of Mac1
and lower expression of progenitor KIT marker indicate a predominant endothelial lineage of SCL-PLAP1VE-cad1CD452 cells. The
percentages6 SD of positive cells are indicated. Three to four experiments for each marker were performed. Abbreviations: FL, Fetal liv-
er; PLAP, placental alkaline phosphatase reporter gene; SCL, stem cell leukaemia gene.
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LTR-EC Activity is Largely Ascribed to Fetal Liver
Developmental Stages
We next asked if LTR-EC activity was restricted to the FL dur-
ing development. The mouse embryonic liver develops at
around stage E8 and ECs forming the microvasculature are
ﬁrst observed by stage E9-E10, concomitant with the appear-
ance of hematopoietic cells [62, 63]. SCL-PLAP1VE-
cad1CD452 cells were detected by E10 (Fig. 4A).
Independently of the developmental stage, most VE-
cad1CD452 cells expressed CD311, however Lyve11 sinusoi-
dal ECs only constituted 506 4% of VE-cad1CD452 popula-
tion by stage E10, progressively incrementing up to 906 5%
by stage E14 (Fig. 4B). To determine when LTR-EC activity ﬁrst
appeared during FL development a number of total unfractio-
nated E10 to E14 FL cells, (0.1-5 x 106 cells) (Table 2), contain-
ing equivalent numbers of SCL-PLAP1VE-cad1CD452 cells
(0.2-1.1 x 104 cells) were transplanted per recipient
Figure 4.
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(Supporting Information Table 3). None of the 9 analyzed
mice receiving E10 FL cells presented donor-derived liver vas-
cular engraftment, whereas a total of 15 out of 17 recipient
mice receiving E11 to E14 FL cells showed SCL-PLAP1 endo-
thelial v.c. in the liver (Table 2). A substantial fraction of the
chimeras with liver vascular engraftment also presented vas-
cular clusters in the heart (7 positive out of 17 transplanted
mice) (Supporting Information Table 4) and hemato/vascular
clusters in the kidneys (not shown). The low SCL-PLAP1VE-
cad1CD452 cell numbers obtained and transplanted from E10
FL could explain the reduction of LTR-EC activity. Alternatively,
FL SCL-PLAP1VE-cad1CD452 cells may acquire LTR-EC activity
as a maturational process along development, analogous to
the maturational events driving the changes in the
reconstitution potential of immature HSC to acquire HSC
properties [50, 63]. Indeed, at E10 a greater proportion of VE-
cad1CD452 cells were negative for Lyve1 (Fig. 4B), a marker
proposed to be associated to maturation of liver endothelial
cells during development [58].
We next analyzed the presence of LTR-EC activity in the
adult liver. Endothelial engraftment potential of adult LSECs,
has been shown by transferring puriﬁed CD311 LSECs or a
LSEC enriched NPCs fraction (LSEC-NPC) into preconditioned
adult mice [26, 29, 32]. Flow cytometry analysis indicated
that 46 2.6% of LSEC-NPC cells were SCL-PLAP1VE-
cadlow1CD452 (Fig. 4A), most expressing the endothelial
markers Lyve1 and CD31 (Fig. 4B). Despite the presence of an
incremented percentage of ECs compared to E12 FL cells, less
Figure 4. Characterization of SCL-PLAP1VE-cad1CD452 cells during liver development and adult liver. FL cells from indicated embryonic
stages and adult liver LSEC-NPC fraction were obtained from SCL-3’Enh-PLAP transgenics. (A): FACS analysis for SCL-PLAP, VE-cad and
CD45 co-expression. SCL-PLAPbright1 cells are gated (left panels) and the percentage of VE-cad1CD452 determined at each developmen-
tal stage. SCL-PLAP1VE-cad1CD452 cells are detected during development and in adult liver (blue gate). Cell suspensions from pooled
E10-E12 FL and from individual E14 FL and adult livers were analyzed. E10, n5 4; E11, n5 6; E12, n5 13; E14, n5 12; adults, n5 4.
(B): VE-cad1CD452 proﬁle for Lyve1 and CD31 endothelial markers expression. Most VE-cad1CD452 express CD31 while the Lyve1 levels
increment with development. Overlaid gray line histograms correspond to unstained controls on VE-cad1CD452 gated cells. E10, n5 3;
E11, n5 6; E12, n5 6; E14, n5 8; adults, n5 3. Percentages 6SD of positive cells are shown. 7AAD1 dead cells were gated out from
the analysis window and they represented 126 4% in FL E10, 86 5% in FL E11, 116 5% in FL E12, 56 2% in E14 FL and 686 17% in
adult liver LSEC-NPC fraction. Embryonic/fetal tissues were obtained from at least 3 independent litters for each stage. (C): The number
of CD311 EC cords/colonies from 500 plated unfractionated and sorted cell populations from E12 FL and adult liver LSEC-NPC fraction is
shown (representative sorting windows shown in B). Incremented EC activity is observed from total (TFL) and sorted VE-
cad1CD45-Lyve11 (V1C2L1) FL cells compared to adult liver-derived counterpart populations. Very low EC activity is identiﬁed in FL VE-
cad1CD45-Lyve12 (V1C2L2) (56 3 colonies) compared to V1C2L1 cells (526 14 colonies). The number of scored wells was as follows:
TFL, n5 5; FL V1C2L1, n5 9; FL V1C2L2, n5 9; adult liver LSEC-NPC, n5 5; adult liver V1C2L1, n5 6. Two to six independent experi-
ments, including simultaneous cultures for FL and adult liver cells, were performed. (D): Images from NBT staining on liver sections from
E11 FL chimera, showing part of a large PLAP1 vascular-like cluster, and an adult liver chimera, transplanted with LSEC-NPC cells, show-
ing PLAP1 sporadic sinusoidal-like cells. Number of adult liver chimeras analyzed, n5 6; sporadic sinusoidal-like cells were observed in
two animals. E11 FL chimeras, n5 6, large vascular clusters observed in all chimeras (see Table 2 and Supporting Information Table 4).
Scale bars 100 lm. Abbreviations: LSECs, liver sinusoidal endothelial cells; NPC, nonparenchymal cell; PLAP, placental alkaline phospha-
tase reporter gene; SCL, stem cell leukaemia gene.
Table 2. Spatial-temporal mapping of LTR-EC activity during development
Donor cells
Hematopoietic chimerism Vascular chimerism
Tissue Stage
Cell no
x106 (ee)
no PLAP1/
Total micea
% PLAP1
(Range values)b
no PLAP1/
Total micec
PLAP1 v.c.a. x1023 cm2
(Range values)
FL E10 0.1-0.14 0/13 0 0/9 0
(2-4)
E11 0.25-0.5 5/6 10.566 6.72 6/6 1.216 0.52
(2-4) (4.9-18) (0.23-1.69)
E12 1.3 5/5 12.846 9.64 5/5 1.456 0.74
(1) (1.6-27) (0.18-2.08)
E14 5 6/6 6.116 5.73 4/6 0.816 0.22
(0.2) (1-13) (0.49-1)
Adult liver 5 0/6 0 0/6 0
AGM E12 0.55 10/12 7.356 5.58 4/10 0.0236 0.036
(2) (0.7-16.5) (0.0012-0.076)
Yolk sac E12 1 5/10 20.366 10.4 0/5 0
(1) (3.4-30)
Receptor mice were transferred with the indicated number of donor cells obtained from the different tissues derived from SCL-30Enh-PLAP
transgenics. Most animals were also cotransplanted with 1 x 106 BM-LacZ1 cells. Mice were analysed at >3 months post-transplant. SCL-PLAP1
hematopoietic chimerism was determined in peripheral blood leukocytes by PCR-PLAP/LacZ and ﬂow cytometry.
aOnly mice presenting PLAP and/or LacZ PCR signal in circulation are included in the study. The number of SCL-PLAP1 chimeras related to the
total analyzed mice is indicated.
bMean values for % SCL-PLAP1 cells in the circulation are shown.
cVascular chimerism was determined by detection of SCL-PLAP1 vascular clusters (v.c.) on liver sections. The number of animals presenting SCL-
PLAP1 v.c. from the total number of analysed mice is shown. The mean6 SD values of tissue area containing the SCL-PLAP1 v.c. referred to the
total tissue area analysed (PLAP1 v.c.a.) are indicated for each group (individual values in Supporting Information Table 4). Data was obtained
from 2-4 independent transplantation experiments for each tissue.
Abbreviations: ee, embryo equivalent; PLAP, placental alkaline phosphatase reporter gene.
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EC cords/colonies were obtained in vitro from LSEC-NPC cells
(Fig. 4C). To exclude any effects promoted by other cells con-
tained in the LSEC-NPC fraction, sorted VE-cad1CD452Lyve11
cells were examined. This analysis conﬁrmed the lower in
vitro EC activity of adult as compared to FL counterpart cells,
indicating that fetal and adult Lyve11 ECs possessed different
proliferative/differentiation potential. To further evaluate LTR-
EC activity, 5 x 106 LSEC-NPCs cells were transplanted per
recipient. Analysis of the host mice at 4 months revealed only
very few SCL-PLAP1 sinusoidal-like cells in the livers from 2
out of 6 chimeras (Fig. 4D, Table 2). This result shows that
adult liver LSEC-NPCs cells lack an inherent potential to recon-
stitute the liver microvasculature when transferred i.v. to Bu-
conditioned newborns.
To further determine if LTR-EC activity was detected in
other locations presenting hematopoietic activity in E12
embryos, we performed ﬂow cytometry analysis and trans-
plantation assays with cells obtained from the yolk sac (YS)
Figure 5.
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and from the aorta-gonads-mesonephros (AGM) region, both
of which are known to contain SCL-PLAP1 cells [39]. Despite
the presence of SCL-PLAP1VE-cad1CD452, Lyve11 cells in
both sites (Supporting Information Fig. 4A, 4B) [57], vascular
grafts were rare in AGM and absent from YS chimeras (Table
2, Supporting Information Fig. 4C, Supporting Information
Table 3). These results suggest that the FL is the principal
source of SCL-PLAP1VE-cad1CD452, Lyve11 cells with LTR-EC
potential.
Analysis of FL Derived Vascular Endothelial Clusters
Integration in the Liver of Young Mice. Implications for
Vascular Graft Functionality
Functional integration of donor-derived endothelium is a pre-
requisite for the recovery/modulation of the targeted organ.
Functional endothelium should provide and respond to signals
necessary for organ formation/regeneration, regulating tissue
growth and cell proliferation. Coordinated growth of endothe-
lium and tissue cell has been shown during liver organogene-
sis [64], regeneration [29], and damage recovery [65]. To
analyze functionality of the v.c. and whether v.c. associated
with cell proliferation during neonatal liver growth we ﬁrst
determined the emergence and expansion of SCL-PLAP1 v.c.
Mice were transplanted with 106 E12 FL cells and the fre-
quency of vascular chimerism and vascular cluster areas
(v.c.a.) assessed at different times post-transplant. For these
experiments we used unfractionated FL cells, as in these con-
ditions the frequency of vascular chimeras was highly incre-
mented compared with sorted populations (Tables 1 and 2).
Sporadic donor-derived cells were readily observed after a
week without obvious SCL-PLAP1 v.c. formation. Clusters
were ﬁrst detected at 3 weeks post-transplantation (5 positive
out of 13 transplanted mice; v.c.a range from positive mice,
0.28-2.34 x1023 cm2) (Fig. 5A). Consistent increment on the
frequency of vascular chimeras occurred by 6 weeks (12 posi-
tive out of 14 recipient mice) with signiﬁcant v.c.a. growth
compared to 3 weeks, (v.c.a range from positive mice 0.19-
7.86 x1023 cm2, Mann–Whitney test, p< .05). By 30 weeks,
all mice presented vascular chimerism (5 positive out of 5
mice analyzed), reaching a v.c.a stabilization or even decrease
(v.c.a. range 0.18-2.18 x1023 cm2) suggesting that vascular
grafts have a limited expansion capability. During this period
the liver presented a 1.7-fold weight increment from 1 to 2
weeks old mice (0.166 0.02 g to 0.286 0.05 g) followed by a
3.2-fold augmentation between 2 and 4 weeks (0,96 0.04 g).
Liver mass incremented at lower rates from 4 to 8 weeks
(1.46 0.1 g, 1.5-fold weight increase) and from 8 to 30 weeks
(1.96 0.2 g, 1.5-fold weight increase) (Fig. 5B). Thus, robust
organ growth is observed between 2-4 weeks, coincidental
with v.c. expansion, and consequently proliferation activity is
expected to occur.
To determine whether v.c. associated with cell prolifera-
tion activity within the 2-4 age interval, livers were analyzed
at a post-transplantation time when v.c. are ﬁrst detected and
active liver growth occurs (3 weeks), and at later times when
graft expansion stabilizes, liver growth slows down and mini-
mal proliferation is expected (12 weeks). Thick liver sections
were stained for BrdU/PLAP and 3D images analyzed using
confocal microscopy. Proliferating BrdU1 cells were evident at
3 weeks and all SCL-PLAP1 v.c. (n5 10) included BrdU1 cells
(Fig. 5C). The majority of these cells appeared to be
hepatocyte-like cells. Moreover, the frequency of BrdU1
nuclei within the tissue area containing the v.c. was signiﬁ-
cantly higher (3.76 1% BrdU1 nuclei) than in tissue areas
without grafts (1.36 0.2% BrdU1 nuclei), indicating a direct
association of grafted cells and proliferating cell foci (Fig. 5D).
At 12 weeks post-transplantation no BrdU1 cells were
observed within the v.c. (n5 10), indicating the absence of
continuing proliferation in the grafted region. Based on these
observations, we propose that the preferential association of
expanding v.c. with proliferating hepatocyte-like cells reﬂects
functional integration of donor-derived endothelium, reminis-
cent of sinusoidal liver endothelial cell activity that mediate
proliferation during regenerative growth [29]. At the moment
we cannot distinguish if at 3 weeks post-transplantation,
expanding donor-endothelium induces the proliferation of
neighboring cells, or whether donor-cells home into prolifera-
tive areas containing high levels of VEGF necessary for EC
expansion. Indeed, both possibilities are not mutually
exclusive.
Analysis of chimeras generated by transplantation with
ubiquitously labeled SCL-PLAP; act-DsRed FL cells did not
result in DsRed1 hepatocyte clusters (Supporting Information
Fig. 5). This ﬁnding is consistent with previous results [35] and
Figure 5. Functional integration of donor-derived vascular graft in the liver at 3 weeks post-transplantation. Livers from mice trans-
planted with E12 FL cells were analyzed at different times post-transplant. (A): Box plot representing the distribution and mean values
of the SCL-PLAP1 vascular cluster area (v.c.a.) at different ages. The total number of analyzed (n) and v.c. positive (v.c.pos) mice is indi-
cated for each age group. Donor-derived v.c. were ﬁrst observed in 3 week-old mice. The mean v.c.a. values were compared between
groups using the U-Mann–Whitney test (**, p< .05). Signiﬁcant increment on v.c.a. are observed from 3 to 6 weeks post-transplant. No
signiﬁcant v.c.a. size increment is observed at long term (from 6 to 30 weeks post-transplant). (B): Box plot representing the mean val-
ues of the liver weight at the different ages. Signiﬁcant liver growth increment is observed at all ages (Student’s t test, **, p< .05) with
maximal weight increment from 2 to 4 weeks (fold increment in brackets). Mice were derived from 2 to 3 transplantation experiments
for each age. (C): Images from Z stacked optical liver sections from 3 and 12 weeks old FL chimeras, stained with antibodies anti-PLAP,
anti-BrdU and DAPI. Representative images from liver regions without (top panel) and with (lower panel) SCL-PLAP1 donor-derived vas-
cular clusters (v.c.) Most BrdU1 proliferating cells looked-like hepatocytes (large size, single or multiple round nuclei, prominent nucleoli
and moderate to low nucleus/cytoplasm ratio [66]), (asterisk, in inset magniﬁed ﬁeld). Very few BrdU1 endothelial-like cells are
observed (arrows, elongated nuclei, vascular lumen location). (D): Percentage of BrdU1 nuclei referred to the total DAPI1 nuclei deter-
mined in regions without v.c. (out v.c.) and within v.c. (in v.c.) as shown in (C). Number of ﬁelds to determine average %BrdU1 values:
n5 12 from one 3weeks old control mouse; n5 14 from out-v.c. and n5 10 from in-v.c., from two 3 weeks old FL chimeras; n5 32
from out-v.c. and n5 12 from in-v.c., from two 12 weeks old FL chimeras. **, Unpaired two-tailed Student’s t test assuming p< .05; (E):
Optical confocal sections from 3D Z-stacked confocal images showing PLAP1 endothelial cells forming part of large and micro-
vasculature (arrows) and forming whole functional donor derived vessels containing blood cells (asterisk) connected with circulation.
Vessels from 7 out of 10 donor-derived v.c. presented circulatory cells. Scale bars 60 lm. Abbreviation: PLAP, placental alkaline phospha-
tase reporter gene.
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suggests that proliferating hepatocytes are not donor derived.
Unexpectedly, very few BrdU1 nuclei among endothelial-like
cells were obtained and we also analyzed the expression of Ki67
and P-H3 as G1/S/G2 and mitosis markers respectively. Howev-
er, we found only very few proliferating liver endothelial cells.
Most Ki67/P-H31 cells were Albumin1 hepatocytes (Supporting
Information Fig. 6). It remains to be elucidated if mechanisms
coordinating neonatal vascular graft/liver growth are similar to
mechanisms acting during adult liver regeneration and whether
endothelial expansion predominantly occurs through elonga-
tion/remodeling of the cell cytoplasm [67] or through prolifera-
tion identiﬁed by different markers [68].
Functionally grafted vasculature has to connect with the
host vascular conduits to integrate into the transport net-
work. The detection of administered ﬂuorescent perfusant or
the presence of circulatory cells within donor-derived vascula-
ture has been used to demonstrate functionality of vascular
grafts [8, 24]. 3D confocal image analysis from v.c. showed
that circulating cells were present within the lumen of PLAP1
vessels at 3 weeks post-transplant (circulating blood cells
identiﬁed in vessels from 7 out of 10 v.c analyzed) (Fig. 5E),
reinforcing the idea that donor-derived vascular clusters repre-
sent functional vasculature perfused by circulation.
DISCUSSION
In the present study, using the expression of SCL-30Enh cis-regu-
latory element in combination with transplantation and in vitro
assays, we have isolated and characterized a novel progenitor
population endowed with multiorgan long-term reconstituting
endothelial (LTR-EC) potential from the E12 FL. Our previous
studies have provided a comprehensive characterization of the
hemato/vascular SCL-30Enh, establishing its activity pattern in a
range of progenitor and mature cell types [39, 41, 69, 70]. Here,
we used the SCL-30Enh-PLAP mouse model to reveal the lineage
commitment and in vivo reconstituting potential of FL SCL-
PLAP1VE-cad1CD452cells. The identiﬁcation of a new EC/EPC
population with LTR-EC potential using the SCL-30Enh expression
vector, opens new avenues for manipulating vascular cells dur-
ing organ development and in a transplantation context, poten-
tially similar to the SCL-30Enh use for basic and translational
studies of HSPCs [40, 71–75].
The FL SCL-PLAP1VE-cad1CD452 population is heteroge-
neous, a fact that might be relevant for its function in transplan-
tation. It is mainly composed by lineage committed sinusoidal
type ECs that express different EC-associated molecules, includ-
ing the sinusoidal marker Lyve1 [57, 58, 76, 77] and present EC
activity in vitro. In addition, the SCL-PLAP1VE-cad1CD452 popu-
lation contains other minor Lyve12 and/or KIT1 cell subsets
endowed with in vitro B lymphoid cell and limited EC activity
and their precise allocation within the hemato/endothelial hier-
archy remains uncertain [49, 50, 61, 78]. Taking into account
that SCL-PLAP1VE-cad1CD452 derived vascular grafts are not
simultaneously detected in all analyzed organs, it is possible
that SCL-PLAP1VE-cad1CD452Lyve11 cells are potentially true
sinusoidal endothelial cells, predominantly contributing to liver
endothelium. Conversely, the minor Lyve12 and/or KIT1 cell
subsets may contribute to a speciﬁc endothelial beds in the
heart, kidney or lung and/or to the SCL-PLAP1CD451 hemato-
poietic cells identiﬁed in v.c. As in vitro assays do not always
reﬂect in vivo potentials, additional cell-surface markers, tran-
scriptional proﬁling and transplantation assays of SCL-PLAP1VE-
cad1CD452Lyve11 cells and Lyve12 cells should allow to more
precisely classifying FL cells with LTR-EC potential.
SCL-PLAP1VE-cad1CD452 cellular heterogeneity could also
contribute to the generation and stabilization of the vascular graft
within an organ via coordinated pro-angiogenic and vasculogenic
actions ascribed to different cell sub-subsets, as proposed before
for postnatal circulating/BM-derived populations with neovascu-
larization potential [3, 6]. As we discuss below, our results suggest
a potential role of transplanted FL HSCs and/or myeloid cells and
their progeny as pro-angiogenic cooperative cells, contributing to
the increment of endothelial engraftment. Accordingly, transplan-
tation of SCL-PLAP1 [35] or SCL-PLAP1VE-cad1 cells, containing
HSPCs [39] resulted in almost 100% of animals presenting liver
vascular engraftment, while mice transplanted with SCL-
PLAP1CD452 or SCL-PLAP1VE-cad1CD452 populations, devoid
of hematopoietic repopulation potential, yielded 23%-33% of vas-
cular chimerism. Taking into consideration that all analyzed host
mice also presented LacZ1 adult BM-derived hematopoietic chi-
merism, this suggested that a speciﬁc cooperative action from FL
HSPCs and/or their hematopoietic cell progeny may constitute a
key factor for achieving efﬁcient EC/EPCs vascular reconstitution,
potentially by exerting pro-angiogenic activities, as no direct FL
HSC-derived EC contribution was observed. Distinctive character-
istics of FL hematopoietic cells can be relevant for their putative
enhanced pro-angiogenic cooperative action. Compared to adult
BM HSCs, counterpart FL cells present a more robust hematopoi-
etic repopulation [79–81], increased migratory responses to che-
motactic signals [82], enhanced trans-endothelial migratory
capacity, [83] and distinctive expression of Mac-1 [43, 84] and VE-
cad [47, 54], molecules potentially involved in their recruitment
to sites of neovascularization [85, 86]. Also, FL HSCs present a
platelet/myeloid lineage-skewed repopulation potential [81, 87],
which can be a potentially relevant issue considering that myeloid
cells constitute one of the main pro-angiogenic hematopoietic
cells recruited to sites of vascular damage [22, 88, 89], also
involved in vessel anastomosis and remodeling during embryo-
genesis [90, 91]. Potential cooperative pro-angiogenic action of
FL-derived myeloid cells may be exerted at short-term post-trans-
plantation, as no donor derived SCL-PLAP1F4/801 myeloid cells
were observed in liver section from long-term chimeras [35] (and
data not shown). Further SCL-PLAP1VE-cad1CD452 cells cotrans-
plantation assays with different FL myeloid/macrophage cell sub-
sets [91, 92] should clarify this issue.
Intrinsic characteristics of EC/EPC populations that are related
to their origin and developmental stage may also account for vas-
cular engraftment potential. Changes in liver endothelial cells dur-
ing development have been associated with modulating marker
expression, including Lyve1 [58, 93]. The microvascular sinusoids
start forming in the FL around E9 of development and can be iden-
tiﬁed by the histological expression of Flk1, Stab1, and CD31. How-
ever, the hyaluronan-receptor Lyve1 emerges in part of the
sinusoids at E10, when sinusoidal lumen formation becomes more
evident [58, 64, 93]. In accordance with this data, we observed
that while most E10 FL SCL-PLAP1VE-cad1CD452 cells expressed
CD31, only about 50% expressed Lyve1. However, by day E11 most
SCL-PLAP1VE-cad1CD452 cells were Lyve11. As the LTR-EC activity
emerged around this time, acquisition of Lyve1 expression might
be correlated with the appearance of LTR-EC activity from the SCL-
PLAP1VE-cad1CD452 population. Acquisitions of other functional
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features, including engulfment capability and emergence of fenes-
trations, have also been associated to liver sinusoidal EC phenotyp-
ic changes along development [58, 93]. However, the implications
of Lyve1 expression on the function of EC/EPC remained specula-
tive. In addition, Lyve1 knock-out mice have no apparent liver phe-
notype [94, 95].
Differences between midgestation FL and adult liver EC/
EPCs may account for the absence of reconstitution potential
from the adult LSEC-NPC cell fraction when transplanted into
newborn mice. Adult liver-derived LSECs and sinusoidal progen-
itor cells have been effectively used for correction of bleeding
disorders [32] and promotion of liver regeneration [27, 29] in
rodents and might thus be considered for therapeutic applica-
tions. However, vascular integration of transplanted adult LSECs
requires extreme and highly damaging preconditioning regime
of the host, including hepatectomy, treatment with toxic agents
for ECs, irradiation or severe genetic predisposition [26, 28,
76], conditions that do not seem to be induced by the here
applied busulfan treatment [96]. FL Lyve11 cells present fea-
tures of immaturity, including the expression of progenitor
associated marker CD34 and the lack of fenestrations [58].
Interestingly, previous reports involving primary postnatal endo-
thelial progenitors from the vascular wall have correlated the
incremented in vitro OP9-EC colony formation potential with
an EC immature status [24]. We also showed that FL Lyve11
cells presented a higher EC cord/colony formation potential
compared to adult counterpart cells, supporting the idea that
FL cells are functionally more immature than adult LSEC cells.
Moreover, comparative PCR-based quantiﬁcation of repopula-
tion of monocrotaline treated mouse liver endothelium indi-
cates that, related to adult liver, donor FL CD311 ECs
presented a more robust repopulation potential [97]. This result
suggests that FL Lyve11 cells, likely responsible for liver vascu-
lar engraftment, possess characteristics of immature progenitor
cells compared to their adult counterparts.
Although the use of primary or in vitro generated EC/EPC
with FL-EC characteristics could be regarded as a more efﬁ-
cient alternative to the use of adult LSEC, it is important to
take into consideration that FL SCL-PLAP1VE-cad1CD452 pop-
ulation reported here or human FL CD311 population
reported by others [97], might include hematopoietic cooper-
ative cells modulating the effective vascular integration of
endothelial lineage committed EC/EPCs. As promoting vasculo-
genesis is an essential step for fostering liver regeneration
and repair [29, 98] or correcting coagulation defects [32, 76],
it will be important to further investigate the characteristics
and mechanisms that confer FL SCL-PLAP1VE-cad1CD452,
Lyve11 population with engraftment advantages.
CONCLUSION
Using the newborn transplantation model, we have character-
ized in the mouse fetal liver a unique SCL-PLAP1VE-
cad1CD452 population, mostly composed by Lyve11 endothe-
lial cells, that is endowed with multiorgan endothelial recon-
stitution potential (LTR-EC activity). Considering clinical
applications, FL SCL-PLAP1VE-cad1CD452 cells may provide a
more robust vascular engraftment than BM-derived [35] or
adult liver-derived EC/EPC populations, constituting a novel
and highly promising source of cells to study vascular recon-
stitution and repair in neonatal preclinical models and also
might help guide the derivation of long term reconstituting
vascular progenitors from pluripotent stem cells.
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